Joe Pantginis

Palatin Technologies, Inc. (NYSE: PTN) spiked dramatically on Friday in response to Thursday's FDA approval of Sprout Pharmaceuticals' female sexual dysfunction drug, flibanserin. Roth Capital analyst Joe Pantginis published a report on Friday predicting that the ruling would reduce...